CoChat
Sign Up
Cited by 290Influenza Virus Research StudiesGlycosylation and Glycoproteins ResearchCarbohydrate Chemistry and Synthesis

The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.

Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase

Open access
Cohen, Miriam, Zhang, Xing-Quan, Senaati, Hooman P, Chen, Hui-Wen, Varki, Nissi M, Schooley, Robert T, Gagneux, Pascal·2013·Virology Journal
DOI 10.1186/1743-422x-10-321PMC PMC3842836
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Influenza A virus (IAV) neuraminidase (NA) cleaves sialic acids (Sias) from glycans. Inhibiting NA with oseltamivir suppresses both viral infection, and viral release from cultured human airway epithelial cells. The role of NA in viral exit is well established: it releases budding virions by cleaving Sias from glycoconjugates on infected cells and progeny virions. The role of NA in viral entry remains unclear. Host respiratory epithelia secrete a mucus layer rich in heavily sialylated glycoproteins; these could inhibit viral entry by mimicking sialylated receptors on the cell surface. It has been suggested that NA allows influenza to penetrate the mucus by cleaving these sialylated decoys, but the exact mechanism is not yet established. METHODS: We tested IAV interaction with secreted mucus using frozen human trachea/bronchus tissue sections, and bead-bound purified human salivary mucins (HSM) and purified porcine submaxillary mucins (PSM). The protective effect of mucus was analyzed using MDCK cells coated with purified HSM and PSM with known Sia content. Oseltamivir was used to inhibit NA activity, and the fluorescent reporter substrate, 4MU-Neu5Ac, was used to quantify NA activity. RESULTS: IAV binds to the secreted mucus layer of frozen human trachea/bronchus tissues in a Sia dependent manner. HSM inhibition of IAV infection is Sia dose-dependent, but PSM cannot inhibit infection of underlying cells. HSM competitively inhibits NA cleavage of 4MU-Neu5Ac, reporter substrate. Human IAV effectively cleaves Sias from HSM but not from PSM, and binds to HSM but not to PSM. CONCLUSION: IAV interacts with human mucus on frozen tissue sections and mucus-coated beads. Inhibition of IAV infection by sialylated human mucus is dose-dependent, and enhanced when NA is inhibited with oseltamivir. Thus NA cleaves sialylated decoys during initial stages of infection. Understanding IAV interactions with host mucins is a promising new avenue for drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1743-422x-10-321

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 IAV binds to secreted mucus in human trachea tissues. Frozen human trachea tissue sections were stained with Hematoxylin and Eosin (H&E), periodic acid Schiff (PAS, mucin staining in pink), Sambucus nigra agglutinin (SNA, binds to Siaα2-6Gal/GalNAc) or TKH2 antibody (binds to Sialyl Tn: Siaα2-6GalNAc on O-linked glycans). Dashed lines specify the location of secreted mucus, which is preserved in the frozen tissues, as seen in H&E and PAS staining. Both SNA and TKH2 bound to the secreted mucus (dark brown staining), indicating abundant potential ligands for IAV binding. TKH2 binding was confined to the lining of the epithelium and the glands, further confirming that the secreted mucus layer is adequately preserved in these tissues. Binding of IAV to the tissues was tested by incubating 600 HAU of virus 1.5 h at room temperature. All three strains bound to the secreted mucus layer (dashed line), and to ciliated cells (cells stained in dark brown). Virus was detected by anti-NP antibodies. Boxed area is enlarged below each image. Scale bar indicates 500 μm, scale bar of enlarged area indicates 50 μm.
Figure 1 IAV binds to secreted mucus in human trachea tissues. Frozen human trachea tissue sections were stained with Hematoxylin and Eosin (H&E), periodic acid Schiff (PAS, mucin staining in pink), Sambucus nigra agglutinin (SNA, binds to Siaα2-6Gal/GalNAc) or TKH2 antibody (binds to Sialyl Tn: Siaα2-6GalNAc on O-linked glycans). Dashed lines specify the location of secreted mucus, which is preserved in the frozen tissues, as seen in H&E and PAS staining. Both SNA and TKH2 bound to the secreted mucus (dark brown staining), indicating abundant potential ligands for IAV binding. TKH2 binding was confined to the lining of the epithelium and the glands, further confirming that the secreted mucus layer is adequately preserved in these tissues. Binding of IAV to the tissues was tested by incubating 600 HAU of virus 1.5 h at room temperature. All three strains bound to the secreted mucus layer (dashed line), and to ciliated cells (cells stained in dark brown). Virus was detected by anti-NP antibodies. Boxed area is enlarged below each image. Scale bar indicates 500 μm, scale bar of enlarged area indicates 50 μm.CC BY · PubMed Central
Figure 2 IAV binding to secreted mucus is Sia-dependent. Human trachea tissue sections were treated with Arthrobacter ureafaciens sialidase (AUS), which cleaves Sias, or with mild sodium periodate (NaIO4), which truncates the Sia side chain. Both treatments reduce IAV binding to the secreted mucus on human trachea tissues compared to untreated control tissues, confirming that IAV binding to the secreted mucus is Sia-dependent. Dashed lines specify location of virus binding to secreted mucus. Scale bar indicates 50 μm.
Figure 2 IAV binding to secreted mucus is Sia-dependent. Human trachea tissue sections were treated with Arthrobacter ureafaciens sialidase (AUS), which cleaves Sias, or with mild sodium periodate (NaIO4), which truncates the Sia side chain. Both treatments reduce IAV binding to the secreted mucus on human trachea tissues compared to untreated control tissues, confirming that IAV binding to the secreted mucus is Sia-dependent. Dashed lines specify location of virus binding to secreted mucus. Scale bar indicates 50 μm.CC BY · PubMed Central
Figure 3 HSM and oseltamivir have additive inhibitory effects. MDCK cells were layered with PSM or HSM at 1,500, 3,200, 12,000 pmol Sia/well or with PBS buffer as control. The cells were challenged for 1h at 37°C with 109 TCID50 of (A) A/PR/8/34(H1N1), (B) A/SD/1/2009(H1N1), (C) A/SD/17/2008(H1N1), or (D) A/Aichi/2/68(H3N2) in the presence (gray bars) or absence (black bars) of 1 μM oseltamivir. Infected cells were identified by staining with anti-NP antibodies, and quantified in twenty randomly selected images from each sample. Experiments were repeated three times, for each experiment the number of infected cells in the PBS-coated sample was set to 1, and the relative number of infected cells for each treatment was calculated. Lower number of infected cells was observed in HSM coated monolayers compared to PBS-coated monolayers for all tested virus strains (A-D, P<0.05). Dose effects of Sia content in HSM-coated samples were observed for three IAV strains (A-B, D). Significant reduction in the number of infected cells in PSM-coated monolayers was observed only for one strain (C, P<0.05). With exception of the A/SD/1/2009(H1N1) strain, oseltamivir did not inhibit infection of cell coated with either PBS or PSM (A, C-D, gray bars). In contrast, addition of oseltamivir to HSM-coated samples further reduced infection of A/PR/8/34(H1N1), A/SD/1/2009(H1N1) strains (A-B). Both of the oseltamivir-insensitive strains, A/SD/17/2008(H1N1) and A/Aichi/2/68(H3N2), were not affected by addition of the drug (C-D). Data was analyzed by 3-way ANOVA, corrected for multiple comparisons using Tukey’s HSD (see Additional file 2 for complete statistical analysis data). Error bars represent standard deviation. *P<0.05, **P<0.005.
Figure 3 HSM and oseltamivir have additive inhibitory effects. MDCK cells were layered with PSM or HSM at 1,500, 3,200, 12,000 pmol Sia/well or with PBS buffer as control. The cells were challenged for 1h at 37°C with 109 TCID50 of (A) A/PR/8/34(H1N1), (B) A/SD/1/2009(H1N1), (C) A/SD/17/2008(H1N1), or (D) A/Aichi/2/68(H3N2) in the presence (gray bars) or absence (black bars) of 1 μM oseltamivir. Infected cells were identified by staining with anti-NP antibodies, and quantified in twenty randomly selected images from each sample. Experiments were repeated three times, for each experiment the number of infected cells in the PBS-coated sample was set to 1, and the relative number of infected cells for each treatment was calculated. Lower number of infected cells was observed in HSM coated monolayers compared to PBS-coated monolayers for all tested virus strains (A-D, P<0.05). Dose effects of Sia content in HSM-coated samples were observed for three IAV strains (A-B, D). Significant reduction in the number of infected cells in PSM-coated monolayers was observed only for one strain (C, P<0.05). With exception of the A/SD/1/2009(H1N1) strain, oseltamivir did not inhibit infection of cell coated with either PBS or PSM (A, C-D, gray bars). In contrast, addition of oseltamivir to HSM-coated samples further reduced infection of A/PR/8/34(H1N1), A/SD/1/2009(H1N1) strains (A-B). Both of the oseltamivir-insensitive strains, A/SD/17/2008(H1N1) and A/Aichi/2/68(H3N2), were not affected by addition of the drug (C-D). Data was analyzed by 3-way ANOVA, corrected for multiple comparisons using Tukey’s HSD (see Additional file 2 for complete statistical analysis data). Error bars represent standard deviation. *P<0.05, **P<0.005.CC BY · PubMed Central
Figure 4 IAV effectively cleaves sialylated HSM. Magnetic beads-conjugated to HSM or PSM were incubated with A/PR/8/34(H1N1), A/Aichi/2/68(H3N2), or buffer at room temperature to allow cleavage of sialylated beads. After 1.5 h incubation the Sia content of the beads was analyzed by DMB-HPLC, and is expressed as percent of Sia content in buffer-incubated beads. Solid bars represent Neu5Ac content, and hatched bars represent Neu5Gc content. Both viruses reduce Neu5Ac content of HSM by 40%-60%, in contrast, only mild cleavage of PSM Sias was observed. ***P<0.001, **P<0.012 *P=0.03 values indicate the significance in difference between Sia content in the virus-treated samples and the corresponding buffer control (two-tailed T-Test, n=3).
Figure 4 IAV effectively cleaves sialylated HSM. Magnetic beads-conjugated to HSM or PSM were incubated with A/PR/8/34(H1N1), A/Aichi/2/68(H3N2), or buffer at room temperature to allow cleavage of sialylated beads. After 1.5 h incubation the Sia content of the beads was analyzed by DMB-HPLC, and is expressed as percent of Sia content in buffer-incubated beads. Solid bars represent Neu5Ac content, and hatched bars represent Neu5Gc content. Both viruses reduce Neu5Ac content of HSM by 40%-60%, in contrast, only mild cleavage of PSM Sias was observed. ***P<0.001, **P<0.012 *P=0.03 values indicate the significance in difference between Sia content in the virus-treated samples and the corresponding buffer control (two-tailed T-Test, n=3).CC BY · PubMed Central
Figure 5 Sia cleavage preference and susceptibility to oseltamivir inhibition. (A) The cleaving preference of IAV NA was tested by incubation of IAV with the fluorescent reporter, 4-methyl-umbelliferyl (4MU), linked to Neu5Ac, Neu5Gc, or 2-keto-3-deoxynononic acid (Kdn) as substrate. All virus strains cleaved Neu5Ac and Neu5Gc but not Kdn. Background from spontaneous degradation of the 4MU-Sia compounds was subtracted from the results. (B) Virus susceptibility to oseltamivir inhibition was tested by incubation of IAV with 2.5 nmol 4MU-Neu5Ac in the presence of 0, 1 or 17.5 μM oseltamivir in triplicates. Certain strains were only partially inhibited by 1 μM oseltamivir, however, all of the strains were inhibited by 17.5 μM oseltamivir. Substrate cleavage was quantified by measuring fluorescence from the released 4MU reporter compound. *P<0.05, **P<0.01 (two-tailed T-Test, n=3).
Figure 5 Sia cleavage preference and susceptibility to oseltamivir inhibition. (A) The cleaving preference of IAV NA was tested by incubation of IAV with the fluorescent reporter, 4-methyl-umbelliferyl (4MU), linked to Neu5Ac, Neu5Gc, or 2-keto-3-deoxynononic acid (Kdn) as substrate. All virus strains cleaved Neu5Ac and Neu5Gc but not Kdn. Background from spontaneous degradation of the 4MU-Sia compounds was subtracted from the results. (B) Virus susceptibility to oseltamivir inhibition was tested by incubation of IAV with 2.5 nmol 4MU-Neu5Ac in the presence of 0, 1 or 17.5 μM oseltamivir in triplicates. Certain strains were only partially inhibited by 1 μM oseltamivir, however, all of the strains were inhibited by 17.5 μM oseltamivir. Substrate cleavage was quantified by measuring fluorescence from the released 4MU reporter compound. *P<0.05, **P<0.01 (two-tailed T-Test, n=3).CC BY · PubMed Central
Figure 6 HSM inhibits IAV cleavage of the 4MU-Neu5Ac reporter substrate. (A) Cleavage of 4MU-Neu5Ac reporter substrate by A/Aichi/2/68(H3N2) was tested in the presence of HSM from two donors, PSM (10 nmol Sia), or PBS buffer. HSM from both donors inhibited the cleavage of 4MU-Ne5Ac. In contrast PSM did not inhibit cleavage of 4MU-Neu5Ac, similar to the buffer control. (B) Cleavage of 0.1 nmol 4MU-Neu5Ac by three IAV strains was tested in the presence of HSM, PSM (4.7 pmol Sia), or PBS buffer in triplicates. All virus strains were inhibited by HSM but not by PSM. Bars represent standard error, *P<0.05, **P<0.01 (two-tailed T-Test, n=3).
Figure 6 HSM inhibits IAV cleavage of the 4MU-Neu5Ac reporter substrate. (A) Cleavage of 4MU-Neu5Ac reporter substrate by A/Aichi/2/68(H3N2) was tested in the presence of HSM from two donors, PSM (10 nmol Sia), or PBS buffer. HSM from both donors inhibited the cleavage of 4MU-Ne5Ac. In contrast PSM did not inhibit cleavage of 4MU-Neu5Ac, similar to the buffer control. (B) Cleavage of 0.1 nmol 4MU-Neu5Ac by three IAV strains was tested in the presence of HSM, PSM (4.7 pmol Sia), or PBS buffer in triplicates. All virus strains were inhibited by HSM but not by PSM. Bars represent standard error, *P<0.05, **P<0.01 (two-tailed T-Test, n=3).CC BY · PubMed Central
Figure 7 Direct binding of IAV to HSM. Direct binding of IAV to bead-bound HSM and PSM was tested. Virus was incubated with the mucus-coated beads in the presence of oseltamivir to inhibit NA activity. Following incubation, beads were washed to remove both non-bound virus and oseltamivir. The bound virus was quantified by measuring NA activity using 4MU-Neu5Ac-reporter method. Average of three independent experiments is shown. As control for non-specific binding, beads conjugated to non-sialylated polymer were used. Black line indicates the background. All virus strains bound to HSM, but only one strain bound to PSM.
Figure 7 Direct binding of IAV to HSM. Direct binding of IAV to bead-bound HSM and PSM was tested. Virus was incubated with the mucus-coated beads in the presence of oseltamivir to inhibit NA activity. Following incubation, beads were washed to remove both non-bound virus and oseltamivir. The bound virus was quantified by measuring NA activity using 4MU-Neu5Ac-reporter method. Average of three independent experiments is shown. As control for non-specific binding, beads conjugated to non-sialylated polymer were used. Black line indicates the background. All virus strains bound to HSM, but only one strain bound to PSM.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

Sorted by citations

See all 290

Related

Metadata

Authors
Cohen, M., Zhang, X.-Q., Senaati, H. P., Chen, H.-W., Varki, N. M., Schooley, R. T., & Gagneux, P.
Affiliations
  • University of California San Diego (US)
  • National Taiwan University (TW)
Corresponding author
Gagneux, Pascal
ORCID
Venue
Virology Journal
Publisher
Springer Science and Business Media LLC
Published
2013-11-22
Volume
10
Issue
1
Pages
321-321
ISSN
1743-422X (ISSN-L)
DOI
10.1186/1743-422x-10-321
PMC
PMC3842836
OpenAlex
W2119621200
Cited by
288
References
56
Citations by year
2026: 12 · 2025: 25 · 2024: 23 · 2023: 27 · 2022: 23 · 2021: 26 · 2020: 26 · 2019: 31 · 2018: 21 · 2017: 21 · 2016: 25 · 2015: 17 · 2014: 11
FWCI
13.12
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Virology Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • University of California, San Diego (#NS047101, P30 CA23100, P30 NS047101)
  • National Cancer Institute (P30-CA-23100, P30CA023100)
  • National Institute of Allergy and Infectious Diseases (U01AI074521)
  • National Institute of Neurological Disorders and Stroke (NS047101, P30NS047101)
Topics
  • Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
Keywords
influenza A virus, neuraminidase, sialic acid, mucus, viral entry, salivary mucins, submaxillary mucin, oseltamivir, respiratory epithelium
MeSH terms
Animals, Bronchi, Cell Line, Dogs, Humans, Mucus, Neuraminidase, Influenza A virus, Saliva, Sialic Acids, Trachea, Viral Proteins, Virus Internalization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review